Bayer Intellectual Property GMBH et al v. Umedica Laboratories Pvt. Ltd.
| Bayer Intellectual Property GMBH, Bayer Pharma AG, Bayer AG and Janssen Pharmaceuticals, Inc. |
| Umedica Laboratories Pvt. Ltd. |
| 1:2023cv01456 |
| December 21, 2023 |
| US District Court for the District of Delaware |
| Richard G Andrews |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on February 1, 2024. A more recent docket listing may be available from PACER.
| Document Text |
|---|
SO ORDERED, re #9 Unopposed Motion to Extend Time (*Reset Answer Deadlines: Umedica Laboratories Pvt. Ltd. answer due 4/29/2024). Signed by Judge Richard G. Andrews on 2/1/2024. (nms)
|
| Filing 9 Unopposed Motion to Extend Time - filed by Bayer AG, Bayer Intellectual Property GMBH, Bayer Pharma AG, Janssen Pharmaceuticals, Inc.. (Fahnestock, Derek) Modified on 2/1/2024 (nms). |
| Filing 8 SUMMONS Returned Executed by Bayer Intellectual Property GMBH, Janssen Pharmaceuticals, Inc., Bayer AG, Bayer Pharma AG.Umedica Laboratories Pvt. Ltd. served on 1/30/2024, answer due 2/20/2024. (Fahnestock, Derek) |
| CORRECTING ENTRY: The motion filed at D.I. 9 has been removed from the docket as the filing was not duel captioned. This case is a member case to MDL 21-3017-RGA-LDH and therefore all filings need captions that include the MDL and the member case. Counsel is to refile the motion accordingly. (nms) |
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) |
| Filing 7 Summons Issued as to Umedica Laboratories Pvt. Ltd. on 12/21/2023. (mkr) |
| Filing 6 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Janssen Pharmaceuticals, Inc. filed by Janssen Pharmaceuticals, Inc. (mkr) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bayer AG for Bayer Intellectual Property GMBH, Bayer Pharma AG filed by Bayer AG, Bayer Intellectual Property GMBH, Bayer Pharma AG. (mkr) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,539,218 B2; and 10,828,310 B2. (mkr) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No earlier than November 14, 2023. Date of Expiration of Patent: U.S. Patent 9,539,218 expires February 17, 2034, with pediatric exclusivity to August 17, 2034, U.S. Patent 10,828,310 expires January 31, 2039, with pediatric exclusivity to July 31, 2039.Thirty Month Stay Deadline: 5/14/2026. (mkr) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mkr) |
| Filing 1 COMPLAINT filed against Umedica Laboratories Pvt. Ltd. (Filing fee $ 405, receipt number ADEDC-4300062.) - filed by Bayer Intellectual Property GMBH, Janssen Pharmaceuticals, Inc., Bayer AG, and Bayer Pharma AG. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Civil Cover Sheet) (mkr) |
| Remark: MDL panel has been advised. (mkr) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
